Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Illumina Laboratory Services, |
RCV000778375 | SCV000914594 | likely pathogenic | Hereditary von Willebrand disease | 2018-12-17 | criteria provided, single submitter | clinical testing | The VWF c.7056C>T (p.Gly2352) variant is a synonymous variant that has been reported in three studies. Diadone et al. (2011) identified the variant in a heterozygous state in three individuals from a single family, all of whom had von Willebrand type 1 disease. The unaffected siblings of the affected individuals did not carry the variant, indicating that it co-segregated with disease. The variant was also reported in trans with a known pathogenic variant in an individual with type 2N disease (Casonato et al. 2016) and to occur with a frequency of <0.01% in a cohort of index cases (James et al. 2007). This variant is reported at a frequency of 0.000064 in the East Asian population of the Exome Aggregation Consortium, but this frequency is based on one allele only in a region of good sequencing coverage. The variant is thus presumed to be rare. Diadone et al. (2011) demonstrated that the p.Gly2352 variant creates a new donor splice site in exon 41, resulting in the deletion of the last 27 nucleotides of exon 41. Functional studies showed that this deletion had a loss of function effect and resulted in 50% of the control secretion level when the variant was expressed in equal amounts with wildtype in FUR4BHK cells and virtually no secretion when expressed alone. Based on the collective evidence, the p.Gly2352 variant is classified as likely pathogenic for von Willebrand disease. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |